

**American Medical Student Association
House of Delegates 2025-Pending**

Introduced by: Board of Trustees (Emergency Resolution) Passed by majority

School(s)/Program(s): AMSA

Subject: Clarification of Relationships with Industry

Type: Amendment by DELETION and ADDITION

WHEREAS in the aftermath of the COVID-19 pandemic, AMSA acknowledges the challenges posed by its membership decline, which limits the ability of the organization to support member activities

WHEREAS AMSA remains committed to addressing these challenges while maintaining its core values and mission.

WHEREAS AMSA recognizes the importance of ensuring transparency and integrity in its financial practices.

WHEREAS AMSA will clearly outline restrictions on pharmaceutical funding to ensure alignment with its Conflict of Interest Policy, mission, and organizational objectives

THEREFORE BE IT RESOLVED that the CBIA of the American Medical Student Association Section XXII be AMENDED BY DELETION AND ADDITION to state:

Section XXII. Governance of Industry Relationships

The following guidelines are to be used by the Association for ~~pharmaceutical and medical device~~ industry relationships:

1. Regarding direct pharmaceutical, ~~health insurance~~ and medical device industry relationships, AMSA will:
 - a. ~~Not accept funding for general budget support which includes grants and funds for programs and research.~~ Accept general budget support if the organization advances AMSA's goals, or provides unique educational value without direction or conditions, and cumulative funding does not exceed 25% of AMSA's total operating budget. Restricted funds are prohibited for website advertising, chapter visits, AMSA Academy, list sales, and co-branded events.

- ~~b. Not accept income from journal advertising, exhibit hall fees, or any other form of sponsorship.~~ Accept journal advertising and exhibit hall fees when providing educational value or advancing AMSA priorities with the understanding that affiliations with the pharmaceutical and medical device industries will clearly be disclosed for members.
 - ~~c. Ban all direct advertisements and sponsorships in its publications and at its events from all pharmaceutical, biotechnology, and medical device related companies except for educational medical devices (as defined in section 24 subsection 4) commonly used in medical school training as well as companies those who manufacture/promote/market/develop products purported to have a direct health benefit (e.g. vitamins, supplements, food derivatives).~~ Affirm that all dictated funding terms must align with AMSA's priorities and all other funds are truly unrestricted such that AMSA maintains its independence in the use of the funds and given to support the mission of AMSA.
 - d. Prohibit samples of medical supplies except in circumstances that protect the integrity of education (e.g. sutures, IUDs, etc.) and prevent the use of samples as a marketing tool.
 - e. Allow contributions of unrestricted medical device samples at the chapter level for educational programs that are independent of any industry input or control and unaccompanied by marketing materials.
2. Regarding non-profit organizations or foundations affiliated with the pharmaceutical, health insurance or medical device industry, AMSA will:
 - a. Accept general budget support if the organization advances AMSA's goals, or provides unique educational value without direction or conditions, and cumulative funding does not exceed 25% of AMSA's total operating budget.
 - b. Accept journal advertising and exhibit hall fees when providing educational value or advancing AMSA priorities with the understanding that affiliations with the pharmaceutical and medical device industries will clearly be disclosed to displayed for members.
 - c. Affirm that all dictated funding terms grants must align with AMSA's priorities and all other funds are truly unrestricted such that AMSA maintains its independence in the use of the funds and given to support the mission of AMSA.
 - d. Affirm that the autonomy of AMSA will be preserved to sustain the freedom to follow its own course, modify both its goals and priorities, and exercise the freedom to take positions on issues that may be unfavorable to its funder.
 - e. Consider non-monetary collaboration with these organizations to be acceptable if they advance AMSA's priorities.
3. Regarding organizations that may accept some funding from the pharmaceutical or medical device industry, AMSA will:

- a. Accept funding and income by the nature of being at least one degree removed from the industry.
 - b. Accept journal advertising and exhibit hall fees in the absence of any other conflicts of interest.
 - c. Collaborate with these organizations in the absence of any other conflicts of interest.
4. Regarding educational medical device and related organization relationships, AMSA will:
- a. Prioritize independent foundations, non-profit organizations, or relevant programs by governmental institutions (e.g. NIH) to provide education on medical devices but in their absence, relationships with companies supplying educational medical devices are acceptable if the devices:
 - i. Are commonly used in medical school training.
 - ii. Are produced by at least two or more manufacturers.
 - iii. Are not de novo.
 - b. Partner with educational medical device companies and non-profit organizations or foundations affiliated with educational medical device companies, if:
 - i. Funding for general budget support, except for journal advertising revenue and exhibit hall fees, will not cumulatively exceed 25% of AMSA's total operating budget.
 - ii. Income from journal advertising or exhibit hall fees is absent any other conflicts of interest.
 - iii. All **dictated funding terms grants** align with AMSA's priorities and all other funds are truly unrestricted such that AMSA maintains its independence in use of the funds and given for the purpose of supporting the mission of AMSA.
 - iv. The autonomy of AMSA will be preserved to sustain the freedom to follow its own course, modify both its goals and priorities, and exercise the freedom to take positions on issues that may be unfavorable to its funder.